If you are interested in participating in any of our current trials, please call the office at (508) 752-1155 and ask to speak with Marie or Nana, our Clinical Research Coordinators. You may need to be examined to determine if you are a candidate for a particular study.

Current Trials

 
 

Genentech
Archway Clinical Trial GR40548

A phase III, multicenter randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in patients with Neovascular age-related Macular Degeneration


Genentech
Yosemite Clinical Trial GR40349

A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab (RO6867461) in Patients with Diabetic Macular Edema


DRCR
Protocol AC

Aflibercept vs. Bevacizumab with deferred Aflibercept for DME


DRCR
Protocol AG

Randomized clinical trial assessing the effects of pneumatic Vitreolysis on vitreomacular traction


DRCR
Protocol AH

Single arm study assessing the effects of pneumatic Vitreolysis on Macular Hole


Hemera Biosciences
HMR-1002

A Phase 1, multi-center, open label study to assess the efficacy and safety of a single dose of the adeno-associated viral vector serotype 2 (AAVCAGsCD59) expressing sCD59 administered via intravitreal injection seven days after a single intravitreal injection of anti-VEGF. All patients considered for enrollment in this study must have treatment naive wet AMD


Alkeus
Saga

A phase 2/3 multicenter, Randomized, double-masked, parallel-group, placebo-controlled study to investigate the safety, pharmacokinetics, tolerability, and efficacy of ALK-001 in Geographic Atrophy Secondary to age-related Macular Degeneration

Genentech
Avenue Trial

The study will allow evaluation of RO6867461 in a treatment-naive patient population (comparison of Arms A, B, C, and D) and an anti-VEGF−incomplete-responder patient population that meets a predefined criterion at Week 12 (comparison between Arms A and E).CNV component area of . 50% of total lesion size by FFA.


Allergan
DARPin Sequoia Trial

This is a multicenter, double-masked, randomized, 100-week, parallel-group, activecontrolled study to evaluate the safety and efficacy of abicipar in treatment-naïve patients with neovascular AMD.


University of Virginia
TOGA

A randomized, double masked, placebo controlled study evaluating ORACEA (subantimicrobial doxycycline) in subjects with geographic atrophy secondary to non-exudative age-related macular degeneration.


Genentech
CHROMA Protocol #GX29176

A Phase III, multicenter, randomized, double-masked, sham-controlled study of efficacy and safety of 10 mg Lampalizumab intravitreal injections administered every 30 or 45 days to patients with geographic atrophy secondary to age-related macular degeneration.


Diabetic Retinopathy Clinical Research
PROTOCOL AA 

Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time.


Genentech
Boulevard Trial Study #: BP30099

A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 28-Week Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of RO6867461 Administered Intravitreally In Patients With Diabetic Macular Edema.


Diabetic Retinopathy Clinical Research Network
PROTOCOL S

A Phase III, multi-center randomized clinical trial, prompt Panretinal Photocoagulation verses Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.

 
 

 

About Clinical Trials

What is a Clinical Trial?

A clinical trial is a study in human volunteers designed to answer a specific health question about the safety or efficacy of a drug, a device, or other interventions. These allow doctors to examine the benefits and risks of using these drugs. Clinical trials are designed to find safe treatments that work in people and new ways to improve health.

Why Participate in a Clinical Trial?

Clinical trials can either enhance a treatment or be a treatment option. Here are a few reasons people choose to participate in studies:

  • Many treatment drugs and tests are free to study participants

  • Successful clinical trials may improve the length and quality of life for study participants

  • Clinical trials provide an opportunity to take positive action by contributing to the understanding of a disease or condition and by furthering treatment options available to others

  • Patients in successful clinical trials are the first to benefit from these cutting-edge treatments

How is a Clinical Trial Conducted?

A consent form, which explains what is involved in the study, is provided to and reviewed with you by members of the Research Team. Being in a study is completely voluntary, and you can change your mind at any time, even if you have signed the consent form.

All studies have what are known as "Inclusion and Exclusion Criteria," which explain what is involved in the study and outline who may participate. You will be monitored carefully during the study, and you will likely be contacted by the Research Team after study procedures are completed. Some studies require more tests and doctor/clinic visits than you would normally have for an illness or condition.

How are Clinical Trial Participants Protected?

US federal agencies including the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) oversee much of the clinical trials in the U.S. to protect the rights and welfare of study participants. Institutional Review Boards (IRBs) oversee the centers where clinical trials are conducted and ensure that a clinical trial is ethical and that study participants’ rights are protected. As a study participant, you have access to the IRB, a volunteer advocate, the physician and the staff conducting the clinical trial.

For more information on participating in clinical trials, please visit:
www.fda.gov
www.nih.gov
www.clinicaltrials.gov

 

Previous Trials

 

Genentech
HARBOR TRIAL
Protocol # FVF4579g

A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study Of The Efficacy And Safety Of 0.5 mg And 2.0 mg Ranibizumab Administered Monthly Or On An As-Needed Basis (PRN) In Patients with Subfoveal Neovascular Age-Related Macular Degeneration.

Genentech
HARBOR TRIAL
Protocol # FVF4579g

A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study Of The Efficacy And Safety Of 0.5 mg And 2.0 mg Ranibizumab Administered Monthly Or On An As-Needed Basis (PRN) In Patients with Subfoveal Neovascular Age-Related Macular Degeneration.

Genentech
SHORE TRIAL
Protocol # FVF4967g

A Phase IV Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with intravitreal Ranibizumab injections in Subjects with macular edema following Retinal Vein Occlusion.


Ophthotech
REGRESS TRIAL
Protocol# OPH1001A

A Phase 2, Randomized, Double-masked, Controlled Trial to establish the safety and efficacy of intravitreous injections of e10030 (anti-pdgf pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration.

Regeneron 
RE-VIEW TRIAL
Protocol # VGFTe-AMD-1124

An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.

Diabetic Retinopathy Clinical Research Network
PROTOCOL T

A randomized, multi-center clinical trial for a comparative Effectiveness of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema.


Genentech 
Ladder Trial

The primary efficacy objective for this study is as follows: To evaluate the relative efficacy of 10-mg/mL, 40-mg/mL, and 100-mg/mL formulations of ranibizumab, delivered via the Implant, RANIBIZUMAB PORT DELIVERY SYSTEM, as measured by the time a patient first requires Implant refill according to protocol-defined refill criteria compared with the control arm (0.5-mg monthly ITV injections of 10-mg/mL formulation) in patients with subfoveal neovascular (wet) age-related macular degeneration (AMD).

Ophthotech 
1004 Trial

A phase III randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista administered in combination with either Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration.


Ophthotech
Eclipse Trial
Protocol# OPH1003

A Phase 3 Randomized, Double-Masked, Controlled Trial To Establish The Safety and Efficacy Of Intravitreous Administration of Fovista™ (Anti Pdgf-B Pegylated Aptamer) Administered In Combination With Lucentis® Compared To Lucentis® Monotherapy Insubjects With Subfoveal Neovascular Age-Related Macular Degeneration.


Ophthotech 
1006 Trial

Subjects will be treated with “Combination Therapy” of IVT Fovista and IVT Anti-VEGF therapy.

Diabetic Retinopathy Clinical Research Network
Protocol V

For Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity.

Eyegate
Macular Edema

To evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution, EGP-437, using the EyeGate® II Drug Delivery System (EGDS) in patients with macular edema (ME) Study subjects will receive 40 mg/mL dexamethasone phosphate solution delivered via transcleral iontophoresis at 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 9.